Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Front Oncol ; 13: 1199043, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37456251

RESUMO

Purpose: Radiation-induced lung injury (RILI) is strongly associated with various clinical conditions and dosimetric parameters. Former studies have led to reducing radiotherapy (RT) doses to the lung and have favored the discontinuation of tamoxifen during RT. However, the monocentric design and variability of dosimetric parameters chosen have limited further improvement. The aim of our study was to assess the incidence of RILI in current practice and to determine clinical and dosimetric risk factors associated with RILI occurrence. Material and methods: Data from 3 out of the 10 top recruiting centers in CANTO-RT, a subset of the CANTO prospective longitudinal cohort (NCT01993498), were retrospectively analyzed for RILI occurrence. This cohort, which recruited invasive cT0-3 cN0-3 M0 breast cancer patients from 2012 to 2018, prospectively recorded the occurrence of adverse events by questionnaires and medical visits at the end of, and up to 60 months after treatment. RILI adverse events were defined in all patients by the association of clinical symptoms and compatible medical imaging. Results: RILI was found in 38/1565 (2.4%) patients. Grade II RILI represented 15/38 events (39%) and grade III or IV 2/38 events (6%). There were no grade V events. The most frequently used technique for treatment was 3D conformational RT (96%). In univariable analyses, we confirmed the association of RILI occurrence with pulmonary medical history, absence of cardiovascular disease medical history, high pT and pN, chemotherapy use, nodal RT. All dosimetric parameters were highly correlated and had close predictive value. In the multivariable analysis adjusted for chemotherapy use and nodal involvement, pulmonary medical history (OR=3.05, p<0.01) and high V30 Gy (OR=1.06, p=0.04) remained statistically significant risk factors for RILI occurrence. V30 Gy >15% was significantly associated with RILI occurrence in a multivariable analysis (OR=3.07, p=0.03). Conclusion: Our study confirms the pulmonary safety of breast 3D RT in CANTO-RT. Further analyses with modern radiation therapy techniques such as IMRT are needed. Our results argue in favor of a dose constraint to the ipsilateral lung using V30 Gy not exceeding 15%, especially in patients presenting pulmonary medical history. Pulmonary disease records should be taken into account for RT planning.

2.
Laryngoscope ; 133(3): 607-614, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-35638238

RESUMO

OBJECTIVES: Head & Neck Paragangliomas have been historically relying on surgery mostly, with worsened quality of life and major sequelae. Conventional external radiation therapy seems to offer an equivalent control rate with a low toxicity profile. The aim of this study was to assess the safety and efficiency of intensity-modulated radiation therapy in Head & Neck paragangliomas. METHODS: This is a retrospective monocentric study conducted in a referral center, including all patients treated with IMRT, whether as an exclusive or post-operative treatment for a tympanic and jugular, carotid, or vagal paraganglioma. Data collection was performed through the manuscript and computerized medical files, including consultation, operative, imaging, pathological analyses, delineation, and treatment planning reports. Success was defined as the complete or partial regression or stabilization without progression, or relapse in accordance with the RECIST criteria. Acute toxicities and long-term sequelae were assessed. RESULTS: Our cohort included 39 patients included between 2011 and 2021: 18 patients treated for a TJ PG (45.9%), 11 patients for a carotid PG (28.4%), and 9 for a vagal PG (23.1%). Twenty-nine patients had IMRT as an exclusive treatment (74.4%), whereas 10 patients had a post-operative complementary treatment (25.6%). Median follow-up in our cohort was 2318 days (average = 2200 days, 237-5690, sd = 1281.9). Among 39 patients, 37 were successfully controlled with IMRT (94.8%), and the toxicity profile was low without any major toxicity. CONCLUSION: IMRT seems an ideal treatment, whether exclusive or post-operative for Head & Neck paragangliomas. LEVEL OF EVIDENCE: 3 Laryngoscope, 133:607-614, 2023.


Assuntos
Neoplasias de Cabeça e Pescoço , Paraganglioma , Radioterapia de Intensidade Modulada , Humanos , Radioterapia de Intensidade Modulada/efeitos adversos , Radioterapia de Intensidade Modulada/métodos , Estudos Retrospectivos , Qualidade de Vida , Neoplasias de Cabeça e Pescoço/radioterapia , Recidiva Local de Neoplasia , Paraganglioma/radioterapia , Paraganglioma/patologia
3.
Rev Prat ; 72(7): 743-746, 2022 Sep.
Artigo em Francês | MEDLINE | ID: mdl-36511961

RESUMO

ADJUVANT TREATMENTS FOR ENDOMETRIAL CANCER Primary treatment for endometrial carcinoma is surgical. Adjuvant treatment is based on risk profile according to histological type, grade, lymphovascular involvement, FIGO stage and genomic profile. Low-risk patients do not need further treatment and intermediate-risk patients may benefit from brachytherapy. Radiation therapy (for pelvic control) and chemotherapy (for metastatic control) may be discussed for high-intermediate risk patients. For high-risk patients, chemotherapy should be given, most often with radiation therapy.


TRAITEMENTS ADJUVANTS DU CANCER DE L'ENDOMÈTRE Le traitement premier des cancers de l'endomètre est chirurgical. Le traitement adjuvant est fondé sur le niveau de risque de rechute qui dépend du type histologique, du grade, de la présence d'emboles, du stade FIGO et du profil génomique. Si le risque est bas, aucun traitement adjuvant n'est recommandé ; s'il est intermédiaire, une curiethérapie est le plus souvent recommandée. À partir du risque intermédiaire haut peuvent se discuter une radiothérapie externe (pour le contrôle pelvien) et une chimiothérapie (pour le contrôle à distance). Enfin, pour les patientes à haut risque de récidive, la chimiothérapie est recommandée, éventuellement associée à une radiothérapie externe.


Assuntos
Braquiterapia , Neoplasias do Endométrio , Feminino , Humanos , Radioterapia Adjuvante , Estadiamento de Neoplasias , Neoplasias do Endométrio/patologia , Neoplasias do Endométrio/cirurgia , Braquiterapia/efeitos adversos , Risco , Quimioterapia Adjuvante , Estudos Retrospectivos
4.
Radiother Oncol ; 161: 198-204, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34144078

RESUMO

PURPOSE: The aim of this study is to correlate locoregional relapse with radiation therapy volumes in patients with rectal cancer treated with neoadjuvant chemoradiation in the ACCORD 12/0405-PRODIGE 02 trial. PATIENTS AND METHODS: We identified patients who had a locoregional relapse included in ACCORD 12's database. We studied their clinical, radiological, and dosimetric data to analyze the dose received by the area of relapse. RESULTS: 39 patients (6.5%) presented 54 locoregional relapses. Most of the relapses were in-field (n = 21, 39%) or marginal (n = 13, 24%) with only six out-of-field (11%), 14 could not be evaluated. Most of them happened in the anastomosis, the perirectal space, and the usual lymphatic drainage areas (presacral and posterior lateral lymph nodes). Only patients treated for a lower rectum adenocarcinoma had a relapse outside of the treated volume. 2 patients with T4 tumors extending into anterior pelvic organs had relapses in anterior lateral and external iliac lymph nodes. CONCLUSIONS: Lowering the upper limit of the treatment field for low rectal tumors increased the risk of out of the field recurrence. For very low tumors, including the inguinal lymph nodes in the treated volume should be considered. Recording locoregional involvement, treated volumes, and relapse areas in future prospective trials would be of paramount interest to refine delineation guidelines.


Assuntos
Recidiva Local de Neoplasia , Neoplasias Retais , Humanos , Linfonodos , Terapia Neoadjuvante , Neoplasias Retais/radioterapia , Fatores de Risco
5.
Curr Oncol Rep ; 21(11): 102, 2019 11 14.
Artigo em Inglês | MEDLINE | ID: mdl-31728650

RESUMO

PURPOSE OF REVIEW: Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS: With the rise of novel therapeutic techniques and medications, many treatment options for both locoregional and distant metastatic disease have become available. The evolving paradigm of metastatic disease now integrates the concept of oligometastatic disease. On top of systemic treatments, patients with low metastatic burden can benefit from curative approaches such as local therapies (surgery, radiotherapy) directed to either primary tumour and distant metastasis. However, data integrating these considerations in the management of metastatic HNSCC is still lacking. Based on this algorithm, we can provide a tailored treatment to each patient with synchronous metastatic HNSCC, according to their age, general condition and metastatic burden.


Assuntos
Neoplasias de Cabeça e Pescoço/patologia , Neoplasias de Cabeça e Pescoço/terapia , Carcinoma de Células Escamosas de Cabeça e Pescoço/secundário , Carcinoma de Células Escamosas de Cabeça e Pescoço/terapia , Algoritmos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Neoplasias de Cabeça e Pescoço/virologia , Humanos , Imunoterapia , Papillomaviridae/isolamento & purificação , Prognóstico , Radioterapia , Carcinoma de Células Escamosas de Cabeça e Pescoço/virologia
6.
Int J Radiat Oncol Biol Phys ; 105(4): 824-833, 2019 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-31404579

RESUMO

PURPOSE: Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients with colorectal cancer treated with surgery or immunotherapy, with adjuvant chemotherapy being discouraged unless there is nodal involvement. Its impact on radiosensitivity is unknown in patients with colorectal cancer. METHODS AND MATERIALS: Patients treated for locally advanced rectal cancer between 2000 and 2016 were studied. Reported points included age, sex, clinical and radiologic tumor stages at diagnosis, modalities of neoadjuvant treatment, posttreatment pathologic staging, tumor regression score, and local, distant relapse-free, and overall survival. An inverse probability of treatment weighting propensity score analysis was performed to evaluate the association of mismatch repair proficiency with surgical and clinical outcomes. RESULTS: Among the 296 patients included, 23 (7.8%) had dMMR. Median follow-up was 43.0 months (interquartile range, 27.9-66.7). Patients with dMMR were significantly younger than the others. After inverse probability of treatment weighting propensity score matching, dMMR patients had higher pathologic downstaging rate (P < .0001), higher tumor regression grade (P = .024), and a longer recurrence-free survival (P < .0001). CONCLUSIONS: dMRR was associated with significant tumor downstaging after neoadjuvant chemoradiation and with increased recurrence-free survival. dMMR patients may have more radiosensitive tumors.


Assuntos
Quimiorradioterapia Adjuvante , Reparo de Erro de Pareamento de DNA/fisiologia , Terapia Neoadjuvante/métodos , Neoplasias Retais/genética , Neoplasias Retais/terapia , Fatores Etários , Idoso , Feminino , Mutação em Linhagem Germinativa , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Intervalo Livre de Progressão , Pontuação de Propensão , Tolerância a Radiação/genética , Neoplasias Retais/mortalidade , Neoplasias Retais/patologia , Estudos Retrospectivos , Fatores Sexuais , Resultado do Tratamento
7.
Technol Cancer Res Treat ; 17: 1533034617748839, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-29343204

RESUMO

INTRODUCTION: Stereotactic hypofractionated radiotherapy is an effective treatment for brain metastases in oligometastatic patients. Its planning is however time-consuming because of the number of organs at risk to be manually segmented. This study evaluates 2 automated segmentation commercial software. METHODS: Patients were scanned in the treatment position. The computed tomography scan was registered on a magnetic resonance imaging and volumes were manually segmented by a clinician. Then 2 automated segmentations were performed (with iPlan and Smart Segmentation). RT STRUCT files were compared with Aquilab's Artistruct segment comparison module. We selected common segmented volume ratio as the main judging criterion. Secondary criteria were Dice-Sørensen coefficients, overlap ratio, and additional segmented volume. RESULTS: Twenty consecutive patients were included. Agreement between manual and automated contouring was poor. Common segmented volumes ranged from 7.71% to 82.54%, Dice-Sørensen coefficient ranged from 0.0745 to 0.8398, overlap ratio ranged from 0.0414 to 0.7275, and additional segmented volume ranged from 9.80% to 92.25%. Each software outperformed the other on some organs while performing worse on others. CONCLUSION: No software seemed clearly better than the other. Common segmented volumes were much too low for routine use in stereotactic hypofractionated brain radiotherapy. Manual editing is still needed.


Assuntos
Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/radioterapia , Processamento de Imagem Assistida por Computador/métodos , Imageamento por Ressonância Magnética/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Tomografia Computadorizada por Raios X/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Feminino , Humanos , Imageamento Tridimensional/métodos , Masculino , Pessoa de Meia-Idade , Órgãos em Risco , Radiocirurgia/métodos , Software
8.
Bull Cancer ; 101(7-8): 730-40, 2014.
Artigo em Francês | MEDLINE | ID: mdl-25091656

RESUMO

There is an increasing number of therapeutic options in breast cancer management. While prognosis improves, the cardiac toxicity related to treatments remains a significant issue. This toxicity has several clinical presentations and can be explained by complex and diverse molecular mechanisms. Systemic treatments (anthracyclines, inhibitors of HER2 signaling pathway, hormone therapy, antiangiogenic agents) and radiotherapy have their own cardiac toxicity. However, the toxicities associated with these treatments may potentiate together and the existence of pre-existing cardiovascular risk factors should be taken into account. The assessment of cardiac hazard evolves toward a multifactorial approach. Several possibilities exist to minimize the incidence of cardiac complications. Those include pharmacological and technological innovations, but also a more accurate selection of patients and a growing involvement of practitioners in the field of cardiac toxicity, which is prerequisite for an early management of cardiac events.


Assuntos
Inibidores da Angiogênese/efeitos adversos , Antraciclinas/efeitos adversos , Antineoplásicos/efeitos adversos , Neoplasias da Mama/terapia , Cardiopatias/prevenção & controle , Coração/efeitos dos fármacos , Coração/efeitos da radiação , Ado-Trastuzumab Emtansina , Anticorpos Monoclonais Humanizados/efeitos adversos , Antineoplásicos Hormonais/efeitos adversos , Bevacizumab , Feminino , Cardiopatias/etiologia , Humanos , Lapatinib , Irradiação Linfática/efeitos adversos , Maitansina/efeitos adversos , Maitansina/análogos & derivados , Quinazolinas/efeitos adversos , Lesões por Radiação/complicações , Medição de Risco , Fatores de Risco , Serina-Treonina Quinases TOR/antagonistas & inibidores , Trastuzumab
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA